FGFR2 and gastric cancer: Another study aiming to explore the ability of miR-494 and FGFR2 to regulate the cancer-initiating cell phenotype and the therapeutic efficacy of lapatinib in HER2-positive gastric cancer found that increased miR-494 expression was able to reduce lapatinib resistance in these cells [90].